GILUPI CellCollector
home CellCollector about gilupi news contact
german version
Circulating tumor cells
Gilupi method
Practice and clinical validation
Special features

GILUPI CellCollector®in vivo CTC isolation


GILUPI Cell Collector Product Image

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved.

The GILUPI CellCollector® has been deployed in more than 2200 patients, the results of lung, prostate, breast and colorectal cancer patients indicate consistent and high CTC detection rates and cell numbers (similar for early and late cancer stages). The GILUPI CellCollector® has a high CTC detection rate of 70% in early and 72% in late cancer stages.

How to use the GILUPI CellCollector® - LINK

Application video

For more information, click here

1st in vivo CTC isolation CE approval worldwide >>
Application possible in all cancer indications, clinical results available for prostate, lung, breast and colorectal cancer >>
Proven safety and functionality >>
70% CTC detection rate >>
CTC detection in all cancer stages >>
GILUPI presentations of clinical results at the following meetings & exhibitions:
DGU (Dresden)
ECCO (Amsterdam)
EAU (Stockholm)
ACTC (Athens)
ISMRC (Paris)
ASCO (Chicago)
EBCC (Vienna)
ELCC (Glasgow)
DKK (Berlin)
MEDICA (Düsseldorf)